Clinical Trial Update: Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy versus placebo in high-risk ER-positive, HER2-negative breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-03-12